厉害了我的所，武汉病毒研究所申请新药瑞得西韦发明专利！
- 主题发起人 神经过的渥太华
- 开始时间
title is bit misleading,
see China Wants to Patent Gilead’s Experimental Coronavirus Drug
... has applied for a patent in China for the use of the antiviral drug, known as remdesivir, in treating the ailment.
see China Wants to Patent Gilead’s Experimental Coronavirus Drug
... has applied for a patent in China for the use of the antiviral drug, known as remdesivir, in treating the ailment.
最后编辑:
- 注册
- 2004-02-10
- 消息
- 12,869
- 荣誉分数
- 3,046
- 声望点数
- 373
- 注册
- 2004-02-10
- 消息
- 12,869
- 荣誉分数
- 3,046
- 声望点数
- 373
最后谁收专利使用的钱？
- 注册
- 2002-01-28
- 消息
- 15,944
- 荣誉分数
- 3,928
- 声望点数
- 373
搜一下 啥都知道了
非洲人民傳唱那首歌《消滅伊波拉》所說：「伊波拉肆虐/人民飽受痛苦/我們祈求上帝/讓伊波拉離開我們的國家/遠離我們的人民/離開我們的家人和朋友/最終殺死伊波拉/別人因伊波拉走了/中國因伊波拉來了……」
浏览附件881126
JK-05 - Wikipedia
JK-05 is a broad-spectrum antiviral drug developed by the Chinese company Sihuan Pharmaceutical along with the Chinese Academy of Military Medical Sciences. It is reported to act as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication. In tests on mice, JK-05 was claimed to show efficacy against a range of RNA viruses, including influenza, Ebola virus and yellow fever, as well as several arenaviruses and bunyaviruses. The chemical structure of JK-05 has not been disclosed as of October 2014, but it is claimed to be a small molecule drug with a comparatively simple structure, which should be readily amenable to synthesis scale-up for mass production if testing is successful. The drug is however admitted to be similar to the Japanese anti-influenza drug favipiravir, developed by Fujifilm Holdings Corp, which has been used effectively to treat patients with Ebola.[1] In addition, WHO committee members mentioned that the drug is a copy product of favipiravir, because patents of favipiravir were already registered in 2006 in China.[2] The drug has been given preliminary approval by the Chinese authorities to be available for Chinese health workers involved in combating the 2014 West African Ebola outbreak, or if Ebola were to spread into mainland China.[3][1][4][5][6][7] Several other Chinese developed antiviral drugs with anti-Ebola activity have also been disclosed,[8] but have not progressed so far through development as JK-05.[citation needed]
- 注册
- 2003-09-30
- 消息
- 79,542
- 荣誉分数
- 23,889
- 声望点数
- 1,373
JK-05 - Wikipedia
en.wikipedia.org
JK-05 is a broad-spectrum antiviral drug developed by the Chinese company Sihuan Pharmaceutical along with the Chinese Academy of Military Medical Sciences. It is reported to act as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication. In tests on mice, JK-05 was claimed to show efficacy against a range of RNA viruses, including influenza, Ebola virus and yellow fever, as well as several arenaviruses and bunyaviruses. The chemical structure of JK-05 has not been disclosed as of October 2014, but it is claimed to be a small molecule drug with a comparatively simple structure, which should be readily amenable to synthesis scale-up for mass production if testing is successful. The drug is however admitted to be similar to the Japanese anti-influenza drug favipiravir, developed by Fujifilm Holdings Corp, which has been used effectively to treat patients with Ebola.[1] In addition, WHO committee members mentioned that the drug is a copy product of favipiravir, because patents of favipiravir were already registered in 2006 in China.[2] The drug has been given preliminary approval by the Chinese authorities to be available for Chinese health workers involved in combating the 2014 West African Ebola outbreak, or if Ebola were to spread into mainland China.[3][1][4][5][6][7] Several other Chinese developed antiviral drugs with anti-Ebola activity have also been disclosed,[8] but have not progressed so far through development as JK-05.[citation needed]
中国已将中国军方研发的一种实验性抗伊波拉药物送往非洲，数量达到数千剂。制造该药的公司表示，计划在那里很快开始人体临床试验。
新浪财经报道，四环医药（Sihuan Pharmaceutical）上周向中国军事医学科学院（简称“军科院”）买下jk-05的商业化权利。该公司表示，它在该药8月“获得军队特需药物批件”后就投入了制造。
四环医药研发部总经理助理、该公司旗下北京澳合药物研究院院长霍彩霞介绍说，中国军方已向西非发运了足以治疗1万人的药物。四环医药的创始人是前军医。摩根士丹利（Morgan Stanley）旗下的私募股权基金持有该公司部分股权。
